Biological metabolic function of the human liver cell line-1 used in bioartificial liver

doi:10.3969/j.issn.2095-4344.2013.18.010

Abstract

Abstract:

BACKGROUND: Our preliminary study found that Chinese human liver cell line-1 has high differentiation ability and good biological metabolic functions, and the human liver cell lines are separated from normal liver tissue on a cell histology which are safer than the tumor-derived liver cell line.
OBJECTIVE: To investigate the biological metabolic functions of Chinese human liver cell line-1 cells in a hybrid bioartificial liver.
METHODS: Fifteen cynomolgus monkeys were randomly divided into the control group (n=5) and the treatment group (n=10), and all the monkeys were used to establish the acute liver failure models. The models in the treatment group were implanted with Chinese human liver cell line-1 established hybrid bioartificial liver through the contact perfusion bioreactor inoculation under micro carrier microgravity.
RESULTS AND CONCLUSION: The serum alanine aminotransferase, total bilirubin, total bile acid, urea nitrogen, creatinine and blood ammonia levels of the cynomolgus monkeys with acute liver failure were increased, while the albumin level and Fischer index were decreased; after treated with hybrid bioartificial liver, serum alanine aminotransferase, total bilirubin, total bile acid, urea nitrogen, creatinine and blood ammonia levels of the cynomolgus monkeys with acute liver failure were recovered to the normal levels. It suggests that Chinese human liver cell line-1 cells in hybrid bioartificial liver have good biological metabolic function with good liver-specific biosynthesis and biological metabolic functions.

Key words: organ transplantation, transplantation and artificial organs, human hepatocytes, artificial organs, hybrid bioartificial liver, liver, liver-specific biosynthesis, cynomolgus monkeys, National 863 Project of China

CLC Number:

R318

Rao Xiao-hui, Jian Guo-deng, Zhang Zhi, Wang Yan, Pan Ming-xin, Gao Yi. Biological metabolic function of the human liver cell line-1 used in bioartificial liver[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(18): 3295-3302.

Figures/Tables 8

References

[1] Bernal W, Auzinger G, Dhawan A, et al. Acute liver failure. Lancet. 2010;376(9736):190-201.

[2] Bismuth H, Figueiro J, Samuel D. What should we expect from a bioartificial liver in fulminant hepatic failure? Artif Organs. 1998;22(1):26-31.

[3] Xue YL, Zhao SF, Zhang ZY, et al. Effects of a bioartificial liver support system on acetaminophen induced acute liver failure canines. World J Gastroenterol. 1999;5(4):308-311.

[4] Rong YH, Liu HL, You SL, et al. Construction and experimental study on off-line hybrid bioartificial liver supporting system with human liver cell line. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2010;24(3): 193-195.

[5] Shi XL, Zhang Y, Chu XH, et al. Evaluation of a novel hybrid bioartificial liver based on a multi-layer flat-plate bioreactor. World J Gastroenterol. 2012;18(28):3752-3760.

[6] Pless G. Bioartificial liver support systems. Methods Mol Biol. 2010;640:511-523.

[7] Miyoshi H, Ehashi T, Kawai H, et al. Three-dimensional perfusion cultures of mouse and pig fetal liver cells in a packed-bed reactor: effect of medium flow rate on cell numbers and hepatic functions. J Biotechnol. 2010;148(4): 226-232.

[8] Dan YY, Yeoh GC. Liver stem cells: a scientific and clinical perspective. J Gastroenterol Hepatol. 2008;23(5):687-698.

[9] Schroeder IS, Wiese C, Truong TT, et al. Differentiation analysis of pluripotent mouse embryonic stem (ES) cells in vitro. Methods Mol Biol. 2009;530:219-250.

[10] Fonsato V, Herrera MB, Buttiglieri S, et al. Use of a rotary bioartificial liver in the differentiation of human liver stem cells. Tissue Eng Part C Methods. 2010;16(1):123-132.

[11] Tsiaoussis J, Newsome PN, Nelson LJ, et al. Which hepatocyte will it be? Hepatocyte choice for bioartificial liver support systems. Liver Transpl. 2001;7(1):2-10.

[12] Nyberg SL, Remmel RP, Mann HJ, et al. Primary hepatocytes outperform Hep G2 cells as the source of biotransformation functions in a bioartificial liver. Ann Surg. 1994;220(1):59-67.

[13] Nagaki M, Miki K, Kim YI, et al. Development and characterization of a hybrid bioartificial liver using primary hepatocytes entrapped in a basement membrane matrix. Dig Dis Sci. 2001;46(5):1046-1056.

[14] Dixit V. Development of a bioartificial liver using isolated hepatocytes. Artif Organs. 1994;18(5):371-384.

[15] Rozga J, Morsiani E, Lepage E, et al. Isolated hepatocytes in a bioartificial liver: A single group view and experience. Biotechnol Bioeng. 1994;43(7):645-653.

[16] Poyck PP, van Wijk AC, van der Hoeven TV, et al. Evaluation of a new immortalized human fetal liver cell line (cBAL111) for application in bioartificial liver. J Hepatol. 2008; 48(2):266-275.

[17] Sivertsson L, Synnergren J, Jensen J, et al. Hepatic differentiation and maturation of human embryonic stem cells cultured in a perfused three-dimensional bioreactor. Stem Cells Dev. 2013;22(4):581-594.

[18] Nyberg SL, Yagi T, Matsushita T, et al. Membrane barrier of a porcine hepatocyte bioartificial liver. Liver Transpl. 2003;9(3): 298-305.

[19] Frühauf JH, Mertsching H, Giri S, et al. Porcine endogenous retrovirus released by a bioartificial liver infects primary human cells. Liver Int. 2009;29(10):1553-1561.

[20] Di Nicuolo G, D'Alessandro A, Andria B, et al. Long-term absence of porcine endogenous retrovirus infection in chronically immunosuppressed patients after treatment with the porcine cell-based Academic Medical Center bioartificial liver. Xenotransplantation. 2010;17(6):431-439.

[21] Yang Q, Liu F, Pan XP, et al. Fluidized-bed bioartificial liver assist devices (BLADs) based on microencapsulated primary porcine hepatocytes have risk of porcine endogenous retroviruses transmission. Hepatol Int. 2010;4 (4):757-761.

[22] Kobayashi N. Life support of artificial liver: development of a bioartificial liver to treat liver failure. J Hepatobiliary Pancreat Surg. 2009;16(2):113-117.

[23] Sharma R, Greenhough S, Medine CN, et al. Three-dimensional culture of human embryonic stem cell derived hepatic endoderm and its role in bioartificial liver construction. J Biomed Biotechnol. 2010;2010:236147.

[24] Mizumoto H, Hayashi S, Matsumoto K, et al. Evaluation of a hybrid artificial liver module based on a spheroid culture system of embryonic stem cell-derived hepatic cells. Cell Transplant. 2012;21(2-3):421-428.

[25] Greenhough S, Medine CN, Hay DC. Pluripotent stem cell derived hepatocyte like cells and their potential in toxicity screening. Toxicology. 2010;278(3):250-255.

[26] Schmelzer E, Triolo F, Turner ME, et al. Three-dimensional perfusion bioreactor culture supports differentiation of human fetal liver cells. Tissue Eng Part A. 2010;16(6): 2007-2016.

[27] Filippi C, Keatch SA, Rangar D, et al. Improvement of C3A cell metabolism for usage in bioartificial liver support systems. J Hepatol. 2004;41(4):599-605.

[28] Harm S, Stroble K, Hartmann J, et al. Alginate-encapsulated human hepatoma C3A cells for use in a bioartificial liver device - the hybrid-MDS. Int J Artif Organs. 2009;32(11): 769-778.

[29] Harimoto N, Taketomi A, Kitagawa D, et al. The newly established human hepatocyte cell line: application for the bioartificial liver. J Hepatol. 2005;42(4):557-564.

[30] Hoekstra R, Nibourg GA, van der Hoeven TV, et al. The HepaRG cell line is suitable for bioartificial liver application. Int J Biochem Cell Biol. 2011;43(10):1483-1489.

[31] Jian GD, Zhang Z, Wang Y, et al. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu. 2011;15(12): 2129-2132.简国登,张志,汪艳,等.新型人源细胞混合型生物人工肝的安全性[J].中国组织工程研究与临床康复,2011,15(12):2129-2132.

[32] The Ministry of Science and Technology of the People’s Republic of China. Guidance Suggestions for the Care and Use of Laboratory Animals. 2006-09-30.中华人民共和国科学技术部. 关于善待实验动物的指导性意见. 2006-09-30.

[33] Xu YZ, Xue K, Gao Y, et al. Shijie Huaren Xiaohua Zazhi. 2010;18(19):1985-1989.徐玉振,薛琨,高毅,等.非人灵长类动物急性肝功能衰竭模型的建立[J].世界华人消化杂志,2010,18(19):1985-1989.

[34] Shakil AO, Kramer D, Mazariegos GV, et al. Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl. 2000;6(2):163-169.

[35] Sass DA, Shakil AO. Fulminant hepatic failure. Liver Transpl. 2005;11(6):594-605.

[36] Castaldo ET, Chari RS. Liver transplantation for acute hepatic failure. HPB (Oxford). 2006;8(1):29-34.

[37] Chamuleau RA, Deurholt T, Hoekstra R. Which are the right cells to be used in a bioartificial liver? Metab Brain Dis. 2005; 20(4):327-335.

[38] Ostapowicz G, Lee WM. Acute hepatic failure: a Western perspective. J Gastroenterol Hepatol. 2000;15(5):480-488.

[39] Pereira SP, McCarthy M, Ellis AJ, et al. Auxiliary partial orthotopic liver transplantation for acute liver failure. J Hepatol. 1997;26(5):1010-1017.

[40] Goss JA, Shackleton CR, Maggard M, et al. Liver transplantation for fulminant hepatic failure in the pediatric patient. Arch Surg. 1998;133(8):839-846.

[41] Esquivel CO, Keeffe EB, Garcia G, et al. Resection versus transplantation for hepatocellular carcinoma. J Gastroenterol Hepatol. 1999;14 Suppl:S37-41.

[42] Lee KK, Kim DG, Moon IS, et al. Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma. J Surg Oncol. 2010;101(1):47-53.

[43] Chan SC. Liver transplantation for fulminant hepatic failure: as early as necessary and as late as possible. J Gastroenterol Hepatol. 2011;26(1):3-4.

[44] Gómez Cabeza de Vaca V, Bernal Bellido C, Alamo Martínez JN, et al. Liver transplantation due to fulminant hepatic failure. Transplant Proc. 2012;44(7):2076-2077.

[45] Lee WM. Acute liver failure. Semin Respir Crit Care Med. 2012;33(1):36-45.

[46] Lucidi V, Buggenhout A, Boon N, et al. Liver transplantation for acute liver failure in adults. Minerva Gastroenterol Dietol. 2008;54(1):49-55.

[47] Ndraha S, Hasan I, Simadibrata M. The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition. Acta Med Indones. 2011;43(1):18-22.

[48] Bajaj JS. Management options for minimal hepatic encephalopathy. Expert Rev Gastroenterol Hepatol. 2008; 2(6):785-790.

[49] Ortiz M, Jacas C, Córdoba J. Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. J Hepatol. 2005;42 Suppl(1):S45-53.

[50] Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3(8):711-715.

[51] Gómez-Lechón MJ, Lahoz A, Castell JV, et al. Evaluation of cytochrome P450 activities in human hepatocytes in vitro. Methods Mol Biol. 2012;806:87-97.